946 Views

Becton Dickinson 

“Market Cap $22.63 B As of May 2014

At a Glance
  • Industry: Medical Equipment & Supplies
  • Founded: 1897
  • Country: United States
  • CEO: Vincent Forlenza
  • Website: www.bd.com
  • Employees: 29,979
  • Sales: $8.17 B
  • Headquarters: Franklin Lakes, New Jersey
Forbes Lists

#744 Global 2000

  • #1143 in Sales
  • #670 in Profit
  • #1560 in Assets
  • #491 in Market value

#83 Innovative Companies (#83 in 2011)

Profile

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences. The BD Medical segment produces medical devices that are used in a wide range of healthcare settings. This segment product include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Diagnostics segment provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect a broad range of infectious diseases, healthcare-associated infections and cancers. This segment products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; and plated media. The BD Biosciences segment produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. This segment product include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson Historical development

1897–1947

BD was founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, two American businessmen who met on a sales trip. The same year the company made its first sale, a Luer-all-glass syringe that sold for $2.50. In 1898, BD acquired its first patent for a medical product. In 1899 the company introduced its first logo which was meant to symbolize guaranteed superior quality of the products provided by BD. In 1904, BD acquired the Philadelphia Surgical Company. This very first acquisition and other early acquisitions significantly expanded the company’s manufacturing ability and product offering. Two years later, BD incorporated in the State of New Jersey and built a manufacturing facility in East Rutherford, the first in the U.S. created specifically for the production of thermometers, hypodermic needles, and syringes. In 1924, BD manufactured its first syringe designed specifically for insulin injection. One year later, BD introduced the BD Yale Luer-Lok Syringe, designed and patented by Fairleigh S. Dickinson, Sr. It provided a simple and secure method of attaching and removing the needle to and from the syringe. Today, luer lock connectors are the standard for syringes in the U.S. In 1947 Joseph Kleiner developed the Evacutainer — a device used to draw blood by vacuum through a needle into a test tube. This product eventually evolved to become the BD Vacutainer Blood Collection system.

1948–1970

In 1948, BD faced new leadership as Fairleigh S. Dickinson, Jr. and Henry P. Becton, sons of the founders, took over the company. Their 24-year tenure was a time of rapid development for BD. The company grew within the U.S. as well as internationally. In 1949, it opened its first manufacturing site outside of New Jersey in Columbus, Nebraska. In 1961, it established a manufacturing facility in Canaan, Connecticut. BD also soon expanded to Canada (1951), Mexico (1952), France (1955), and Brazil (1956). The tenure of Fairleigh S. Dickinson, Jr. and Henry P. Becton was also a time of significant product innovation. In 1950, BD’s first sterile disposable product, a blood collection set, was developed and sold to the American Red Cross. In 1954, BD introduced the first completely disposable syringe made of glass: BD Hypak. This innovative product was used in a large-scale field test of the polio vaccine developed by Dr. Jonas Salk. One year later, BD entered the microbiology field through the acquisition of the Baltimore Biological Laboratory. In 1961, the company introduced its disposable BD Plastipak syringe. Under the new leadership the company also went public (1962) and appeared for the first time in the Fortune 500 list (1970).

1973–1995

In 1973, BD added another U.S. facility —a research center in Durham, North Carolina in Research Triangle Park. The center was established to help the company meet United States Environmental Protection Agency (EPA) requirements, research improved manufacturing and process methods, and develop future innovative technologies. In 1975, BD Pharmaceutical Systems Europe acquired an important patent for a prefilled syringe injecting heparin. In 1980, BD developed its first automated system for mycobacteria testing — the BD BACTEC 460TB System. The next year brought significant signs of the company’s development as sales surpassed the $1 billion milestone and a new plant in Plymouth,England was constructed to serve the European markets. Five years later BD moved its corporate headquarters to Franklin Lakes, New Jersey (current HQ location.) Also in 1986, BD acquired Fabersanitas Industrial, a major Spanish syringe manufacturer as well as Deseret Medical, a vascular access devices manufacturer. The last three years of the 1980s also showed growth in Asia (manufacturing facilities in Singapore and Japan.) Furthermore, BD became the first company to introduce a safety-engineered syringe — BD Safety-Lok (1988) and acquired the Beaver Blade Company, a manufacturer of high-quality surgical blades. The first half of the next decade was very important to BD’s development. The company opened a central distribution center in Temse, Belgium (1992) and entered India and China (1995.) BD also introduced a device that offered needle stick protection following blood-drawing procedures — BD Vacutainer Safety-Lok Blood Collection Set.

1999–2006

In 1999, as BD passed more than 100 years of presence in the medical devices industry, BD announced its new corporate identity. Numerous independent brand names were replaced by a single name: BD. In addition, the company symbol that is used today was introduced. BD also named Edward J. Ludwig as the company’s president. Ludwig was also named Chief Executive Officer (2000) and Chairman of the Board of Directors (2002). On February 9, 1999, BD announced the acquisition of Biometric Imaging, Inc. (BMI), a privately held company serving the transfusion medicine, infectious diseases, and oncology markets. On December 20, 2000, BD signed an agreement to acquire Gentest Corporation, a privately held company serving the life sciences market in the areas of drug metabolism and toxicology testing of pharmaceutical candidates. During that time, BD also got heavily involved in global health issues announcing a five-year maternal and neonatal tetanus world-wide elimination partnership with UNICEF (1999), launching the BD Safety Compliance Initiative (2000), and pledging $1 million contribution to the International AIDS Vaccine Initiative (2002.) In 2003 and 2004, BD introduced several innovative products: BD FACSAria Cell Sorterthe — first entirely new instrument in the next-generation portfolio of flow cytometers (2003), BD Accuspray — a nasal drug delivery system for administering vaccines (2003), BD.id — a patient identification system designed to limit the potential for medical errors in specimen collection (2003), and the world’s first “intelligent” insulin pump and glucose monitoring system, a wireless system consisting of a Medtronic MiniMed Paradigm 512 Insulin Pump and Paradigm Link Blood Glucose Monitor, co-developed with BD. In the beginning of the 21st century BD also invested in growing its business by acquiring several strategically important companies. In 2001, it acquired the Gentest Corporation, a leading in drug metabolism and toxicology testing company. In 2004, BD completed the acquisition of Atto Bioscience Acquired, a company specializing in optical instrumentation, software, and reagents for real-time analysis of interactions taking place in living cells. In 2005 BD entered the field of proteomics through its acquisition of FFE Weber GmbH, which specialized in the separation and fractionation of complex proteins. 2006 was also an important year to document BD’s growth as the company acquired GeneOhm Sciences — a leader in the development of molecular diagnostic testing for the rapid detection of bacterial organisms and TriPath Imaging -acancer diagnostics company.”

*Information from Forbes.com and Wikipedia.org

**Video published on YouTube by “BDCorporate